TOP TEN perturbations for 1552758_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552758_at
Selected probe(set): 205659_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552758_at (205659_at) across 6673 perturbations tested by GENEVESTIGATOR:

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)

Relative Expression (log2-ratio):-5.2294292
Number of Samples:6 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted).

HCC827 / A-549

Relative Expression (log2-ratio):4.7402835
Number of Samples:6 / 6
Experimental HCC827
Human primary cancer cell line derived from the lung of a patient with non-small-cell lung cancer. Synonyms:HCC-827; HCC0827 Cellosaurus code:
Control A-549
Human primary cancer cell line derived from the lung of a patient with carcinoma. Synonyms:A 549; A549; NCI-A549; A549/ATCC; hA549 Cellosaurus code:

4-hydroxytamoxifen study 1 (empty vector) / FoxO3 H212R overexpr. study 1

Relative Expression (log2-ratio):-4.632209
Number of Samples:3 / 3
Experimental 4-hydroxytamoxifen study 1 (empty vector)
Human umbilical vein endothelial cells (HUVECs) transfected with empty retroviral pBabe puro vector designed for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---
Control FoxO3 H212R overexpr. study 1
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP FoxO3.A3.ER.H212R vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of mutated FoxO3 (forkhead box O3) H212R, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)

Relative Expression (log2-ratio):-4.573848
Number of Samples:6 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted).

FoxO3 overexpr. study 1 / 4-hydroxytamoxifen study 1 (empty vector)

Relative Expression (log2-ratio):4.488778
Number of Samples:3 / 3
Experimental FoxO3 overexpr. study 1
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP-FoxO3.A3.ER vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of FoxO3 (forkhead box O3), treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---
Control 4-hydroxytamoxifen study 1 (empty vector)
Human umbilical vein endothelial cells (HUVECs) transfected with empty retroviral pBabe puro vector designed for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---

FoxO3 H212R overexpr. study 1 / transfected HUVEC sample (mutated FoxO3 H212R)

Relative Expression (log2-ratio):4.4654217
Number of Samples:3 / 3
Experimental FoxO3 H212R overexpr. study 1
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP FoxO3.A3.ER.H212R vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of mutated FoxO3 (forkhead box O3) H212R, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---
Control transfected HUVEC sample (mutated FoxO3 H212R)
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP-FoxO3.A3.ER vector designed for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of FoxO3 (forkhead box O3), without 4OHT. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, and harvested after 12 hours for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments.

glioma study 16 (LN-18) / normal astrocyte sample

Relative Expression (log2-ratio):-4.3060503
Number of Samples:2 / 3
Experimental glioma study 16 (LN-18)
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)

Relative Expression (log2-ratio):4.26495
Number of Samples:2 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.

ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):4.088274
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)

Relative Expression (log2-ratio):4.033388
Number of Samples:4 / 2
Experimental lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).